- Home
- TLSI vs DMB Comparison
TLSI vs DMB Comparison
Compare TLSI & DMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- DMB
- Stock Information
- Founded
- TLSI 2010
- DMB 2013
- Country
- TLSI United States
- DMB United States
- Employees
- TLSI N/A
- DMB N/A
- Industry
- TLSI Medical Specialities
- DMB Trusts Except Educational Religious and Charitable
- Sector
- TLSI Health Care
- DMB Finance
- Exchange
- TLSI Nasdaq
- DMB Nasdaq
- Market Cap
- TLSI 244.3M
- DMB 196.9M
- IPO Year
- TLSI N/A
- DMB N/A
- Fundamental
- Price
- TLSI $4.70
- DMB $10.80
- Analyst Decision
- TLSI Strong Buy
- DMB
- Analyst Count
- TLSI 4
- DMB 0
- Target Price
- TLSI $11.13
- DMB N/A
- AVG Volume (30 Days)
- TLSI 131.5K
- DMB 76.6K
- Earning Date
- TLSI 11-13-2025
- DMB 01-01-0001
- Dividend Yield
- TLSI N/A
- DMB 4.17%
- EPS Growth
- TLSI N/A
- DMB N/A
- EPS
- TLSI N/A
- DMB N/A
- Revenue
- TLSI $35,990,000.00
- DMB N/A
- Revenue This Year
- TLSI $56.71
- DMB N/A
- Revenue Next Year
- TLSI $52.25
- DMB N/A
- P/E Ratio
- TLSI N/A
- DMB N/A
- Revenue Growth
- TLSI 45.50
- DMB N/A
- 52 Week Low
- TLSI $3.42
- DMB $8.94
- 52 Week High
- TLSI $5.88
- DMB $11.79
- Technical
- Relative Strength Index (RSI)
- TLSI 45.51
- DMB 64.00
- Support Level
- TLSI $4.87
- DMB $10.76
- Resistance Level
- TLSI $5.18
- DMB $10.86
- Average True Range (ATR)
- TLSI 0.23
- DMB 0.07
- MACD
- TLSI -0.01
- DMB -0.00
- Stochastic Oscillator
- TLSI 44.74
- DMB 70.37
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.